Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends

Sep 2023| PHM276A| BCC Publishing

Report Highlights

The global acute myeloid leukemia (AML) treatments market should reach $6.1 billion by 2028 from $3.8 billion in 2023 at a compound annual growth rate (CAGR) of 10.0% for the forecast period of 2023 to 2028.

Report Includes

  • 42 data tables and 57 additional tables
  • An overview of the global market for acute myeloid leukemia (AML) treatment
  • Analyses of global market trends, with data from 2020 to 2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
  • Highlights of the market potential and characterization of AML market based on treatment type, route of administration type, end-users, distribution channel, region
  • Coverage of various risk factors associated with AML, such as exposure to radiation or chemicals, genetic disorders, and weakened immune system
  • Description of major treatment options for AML such as, chemotherapy, targeted therapy, and stem cell transplantation
  • Information on recent mergers, acquisitions, collaborations, agreements, partnerships, product launches, and expansions in the market and a relevant patent analysis
  • Detailed company profiles of major players in the market of the industry, including AbbVie, Daiichi Sankyo, GlaxoSmithKline PLC, Pfizer Inc. and Servier

Report Scope

This report aims to comprehensively study the market size of AML and treatments for a global market. Current and historical market revenues can be estimated based on treatment type, route of administration, end use, distribution channel and region.

Frequently Asked Questions (FAQs)

The global acute myeloid leukemia market is projected to grow from $3.5 billion in 2022 to $6.1 billion in 2028, at a compound annual growth rate (CAGR) of 10.0% during the forecast period.
Growth in this market is fueled by a worldwide increase in aging populations and an increased prevalence of AML. Technological innovation is an additional important catalyst driving the adaptation and increase in the use these drugs are the major factors driving the market growth.
The global acute myeloid leukemia market is segmented based on the product type such targeted therapy, anthracycline drugs, other chemotherapies and by geographic region.
Targeted therapy segment will dominate the market by the end of 2028.
North America (49.3%) holds the highest share in the market.
Key companies in the market include Bristol Myers Squibb, Sanofi-Aventis, Pfizer, Novartis and Amgen.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $3.5 billion
Market size forecast $6.1 billion
Growth rate CAGR of 10.0%
Units considered $ Millions
Segments covered Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (ROW)
Countries covered U.S., Canada, Germany, France, U.K., Italy, Spain, Rest of Europe, Japan, China, India, Rest of Asia-Pacific, and Middle East and Africa.
Key Market Drivers
  • Growing Elderly Population
  • Increasing Incidence and Prevalence
  • Advancements in Molecular Diagnostics
  • Minimal Residual Disease (MRD) Monitoring
  • Gene Expression Profiling
  • Fusion Gene Detection
  • Liquid Biopsies
  • R&D
  • Regulatory Environment
  • Personalized Medicine
  • Collaborative Efforts
  • Patient Advocacy and Awareness
Companies studied
  • GSK PLC.
  • MERCK & CO. INC.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Title/Chapter NamePagesMember Price
Full Report: Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends122Free
Chapter- 1: Introduction4Free
Chapter- 2: Summary and Highlights4Free
Chapter- 3: Market Overview and Definitions8Free
Chapter- 4: Market Dynamics 7Free
Chapter- 5: Impact of COVID-192Free
Chapter- 6: Market Breakdown by Region8Free
Chapter- 7: Market Breakdown by Treatment Type4Free
Chapter- 8: Market Breakdown by Route of Administration6Free
Chapter- 9: Market Breakdown by Product7Free
Chapter- 10: ESG Development7Free
Chapter- 11: Emerging Trends and Technologies1Free
Chapter- 12: Competitive Landscape6Free
Chapter- 13: Patent Analysis4Free
Chapter- 14: Pipeline Analysis14Free
Chapter- 15: M&A and Venture Funding Outlook2Free
Chapter- 16: Company Profiles37Free
Chapter- 17: Appendix: Acronyms1Free
Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.